94 related articles for article (PubMed ID: 19956878)
1. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.
Gazzerro P; Malfitano AM; Proto MC; Santoro A; Pisanti S; Caruso MG; Notarnicola M; Messa C; Laezza C; Misso G; Caraglia M; Bifulco M
Oncol Rep; 2010 Jan; 23(1):171-5. PubMed ID: 19956878
[TBL] [Abstract][Full Text] [Related]
2. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.
Malfitano AM; Laezza C; Pisanti S; Gazzerro P; Bifulco M
Br J Pharmacol; 2008 Mar; 153(5):1003-10. PubMed ID: 18157162
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.
Sarnataro D; Pisanti S; Santoro A; Gazzerro P; Malfitano AM; Laezza C; Bifulco M
Mol Pharmacol; 2006 Oct; 70(4):1298-306. PubMed ID: 16822929
[TBL] [Abstract][Full Text] [Related]
4. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.
Malfitano AM; Laezza C; Galgani M; Matarese G; D'Alessandro A; Gazzerro P; Bifulco M
Pharmacol Res; 2012 Mar; 65(3):365-71. PubMed ID: 22123497
[TBL] [Abstract][Full Text] [Related]
5. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Troiani T; Lockerbie O; Morrow M; Ciardiello F; Eckhardt SG
Mol Cancer Ther; 2006 Jul; 5(7):1883-94. PubMed ID: 16891475
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
Gary-Bobo M; Elachouri G; Scatton B; Le Fur G; Oury-Donat F; Bensaid M
Mol Pharmacol; 2006 Feb; 69(2):471-8. PubMed ID: 16282221
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
[TBL] [Abstract][Full Text] [Related]
8. Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.
Foltin RW; Haney M
Pharmacol Biochem Behav; 2007 Apr; 86(4):766-73. PubMed ID: 17445873
[TBL] [Abstract][Full Text] [Related]
9. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
12. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus.
Rigamonti AE; Giordani C; Bonomo SM; Cella SG; Müller EE
Eur J Pharmacol; 2006 Aug; 542(1-3):116-20. PubMed ID: 16806163
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.
Ciaglia E; Torelli G; Pisanti S; Picardi P; D'Alessandro A; Laezza C; Malfitano AM; Fiore D; Pagano Zottola AC; Proto MC; Catapano G; Gazzerro P; Bifulco M
Oncotarget; 2015 Jun; 6(17):15464-81. PubMed ID: 26008966
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Zhao S; Cai J; Bian H; Gui L; Zhao F
Cancer Invest; 2009 Jul; 27(6):636-40. PubMed ID: 19387877
[TBL] [Abstract][Full Text] [Related]
16. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.
Maccioni P; Pes D; Carai MA; Gessa GL; Colombo G
Behav Pharmacol; 2008 May; 19(3):197-209. PubMed ID: 18469537
[TBL] [Abstract][Full Text] [Related]
17. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
18. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
20. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
Järbe TU; DiPatrizio NV; Li C; Makriyannis A
Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
